JP2022539256A5 - - Google Patents
Info
- Publication number
- JP2022539256A5 JP2022539256A5 JP2022500099A JP2022500099A JP2022539256A5 JP 2022539256 A5 JP2022539256 A5 JP 2022539256A5 JP 2022500099 A JP2022500099 A JP 2022500099A JP 2022500099 A JP2022500099 A JP 2022500099A JP 2022539256 A5 JP2022539256 A5 JP 2022539256A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962869662P | 2019-07-02 | 2019-07-02 | |
| US62/869,662 | 2019-07-02 | ||
| PCT/US2020/040299 WO2021003157A1 (en) | 2019-07-02 | 2020-06-30 | Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022539256A JP2022539256A (ja) | 2022-09-07 |
| JP2022539256A5 true JP2022539256A5 (https=) | 2023-06-16 |
| JPWO2021003157A5 JPWO2021003157A5 (https=) | 2023-06-16 |
| JP7595055B2 JP7595055B2 (ja) | 2024-12-05 |
Family
ID=71614984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022500099A Active JP7595055B2 (ja) | 2019-07-02 | 2020-06-30 | ｅＩＦ４Ｅ阻害４－オキソ－３，４－ジヒドロピリド［３，４－Ｄ］ピリミジン化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11286268B1 (https=) |
| EP (1) | EP3994139A1 (https=) |
| JP (1) | JP7595055B2 (https=) |
| KR (1) | KR20220061945A (https=) |
| CN (1) | CN114269756B (https=) |
| AR (1) | AR119339A1 (https=) |
| AU (1) | AU2020299362B2 (https=) |
| BR (1) | BR112021026682A2 (https=) |
| CA (2) | CA3085255A1 (https=) |
| CL (1) | CL2021003573A1 (https=) |
| IL (1) | IL289456A (https=) |
| PY (1) | PY2031844A (https=) |
| TW (1) | TWI748541B (https=) |
| UY (1) | UY38773A (https=) |
| WO (1) | WO2021003157A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220378821A1 (en) * | 2019-07-02 | 2022-12-01 | Effector Therapeutics, Inc. | Methods of treating braf-mutated cancer cells |
| EP4076438A4 (en) * | 2019-12-18 | 2023-11-29 | Merck Sharp & Dohme LLC | BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HERPES VIRUSES |
| WO2021240337A1 (en) * | 2020-05-27 | 2021-12-02 | Effector Therapeutics, Inc. | Covalent modifiers of eif4e inhibiting compounds |
| JP2023554521A (ja) | 2020-12-22 | 2023-12-27 | ファイザー・インク | Ｅｉｆ４ｅ阻害剤の固体形態 |
| JP2025539263A (ja) * | 2022-11-10 | 2025-12-04 | リボメトリックス，インコーポレイティド | ｅＩＦ４Ｅ阻害剤としての化合物及び組成物、ならびにそれらの使用 |
| TW202428278A (zh) * | 2022-12-23 | 2024-07-16 | 大陸商南京聖和藥業股份有限公司 | 作為ｅＩＦ４Ｅ抑制劑的化合物及其應用 |
| IL326137A (en) | 2023-07-28 | 2026-03-01 | Cogent Biosciences Inc | PI3K inhibitors |
| WO2025101516A1 (en) * | 2023-11-06 | 2025-05-15 | Ribometrix, Inc. | Methods of using eif4e inhibitors for treating cancer |
| WO2025120599A1 (en) * | 2023-12-08 | 2025-06-12 | Ribometrix, Inc. | METHODS OF USING eIF4E INHIBITORS FOR TREATING CANCER |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080255161A1 (en) * | 2007-04-11 | 2008-10-16 | Dmitry Koltun | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| US20110065671A1 (en) * | 2008-05-19 | 2011-03-17 | Harris Joel M | Bicyclic heterocycle derivatives and use thereof as gpr119 modulators |
| TW201412740A (zh) | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
| WO2014179237A1 (en) | 2013-04-29 | 2014-11-06 | Vanderbilt University | Substituted 3-benzylquinoxalin-4(3h)-one analogs as positive allosteric modulators of muscarinic acetycholine receptor m1 |
| WO2015120350A2 (en) | 2014-02-07 | 2015-08-13 | Effector Therapeutics, Inc. | Compositions and methods for treating fibrotic disease |
| TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
-
2020
- 2020-06-30 CN CN202080059936.5A patent/CN114269756B/zh active Active
- 2020-06-30 CA CA3085255A patent/CA3085255A1/en active Pending
- 2020-06-30 EP EP20740483.1A patent/EP3994139A1/en active Pending
- 2020-06-30 BR BR112021026682A patent/BR112021026682A2/pt unknown
- 2020-06-30 US US16/916,820 patent/US11286268B1/en active Active
- 2020-06-30 TW TW109122116A patent/TWI748541B/zh active
- 2020-06-30 KR KR1020227002902A patent/KR20220061945A/ko not_active Ceased
- 2020-06-30 WO PCT/US2020/040299 patent/WO2021003157A1/en not_active Ceased
- 2020-06-30 CA CA3188446A patent/CA3188446A1/en active Pending
- 2020-06-30 JP JP2022500099A patent/JP7595055B2/ja active Active
- 2020-06-30 AU AU2020299362A patent/AU2020299362B2/en active Active
- 2020-07-02 UY UY0001038773A patent/UY38773A/es not_active Application Discontinuation
- 2020-07-02 AR ARP200101877A patent/AR119339A1/es not_active Application Discontinuation
- 2020-07-02 PY PY202002031844A patent/PY2031844A/es unknown
-
2021
- 2021-12-28 IL IL289456A patent/IL289456A/en unknown
- 2021-12-30 CL CL2021003573A patent/CL2021003573A1/es unknown
-
2022
- 2022-01-28 US US17/587,185 patent/US20230108594A1/en not_active Abandoned